According to Arcus Biosciences
's latest financial reports the company has A$1.71 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | A$1.11 B | -24.86% |
2022-12-31 | A$1.48 B | 115.42% |
2021-12-31 | A$0.68 B | -27.37% |
2020-12-31 | A$0.94 B | 252.4% |
2019-12-31 | A$0.26 B | -26.16% |
2018-12-31 | A$0.36 B | 61.81% |
2017-12-31 | A$0.22 B | 64.04% |
2016-12-31 | A$0.13 B |